Browsing Tag
major depressive disorder
15 posts
Genetic stratification reframes HMNC Brain Health’s BH-200 Phase 2b data and revives precision psychiatry strategy at ACNP
Find out how HMNC Brain Health’s Phase 2b BH-200 data at ACNP reframed clinical risk and revived precision psychiatry strategy in depression.
Can Mind Medicine’s $242.8m war chest carry MM120 through three Phase III wins in 2026?
Mind Medicine strengthens its balance sheet with $242.8M funding and eyes three pivotal Phase III data readouts for MM120 in 2026. See why this matters.
FDA gives CAPLYTA the go-ahead for major depressive disorder, boosting hopes for better remission rates
Find out how CAPLYTA’s FDA approval for major depressive disorder could redefine depression treatment and improve remission outcomes.
FDA approves JNJ’s CAPLYTA for depression: Is this a new hope for MDD remission?
Johnson & Johnson secures FDA approval for CAPLYTA in major depressive disorder. Find out how this expands safe treatment options for difficult-to-treat depression.
AbbVie’s $1.2bn bet on Gilgamesh’s bretisilocin signals a bold push into next-generation antidepressants
AbbVie to acquire Gilgamesh’s bretisilocin for up to $1.2B to expand its psychiatry pipeline. Find out how this short-acting psychedelic could reshape MDD care.
Johnson & Johnson to acquire Intra-Cellular Therapies in $14.6bn deal
Johnson & Johnson has announced its largest biotech acquisition in over a year, agreeing to purchase Intra-Cellular Therapies…
Neumora Therapeutics’ KOASTAL-1 study of navacaprant for MDD falls short on primary endpoint
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company specialising in neuroscience, has announced results from the KOASTAL-1…
Suven life sciences reports rapid-acting depression treatment breakthrough with ropanicant in phase-2a trial
Suven Life Sciences’ Ropanicant delivers rapid antidepressant effects in Phase-2a trial for MDD. See the results, safety profile, and what’s next.
Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) is seeking U.S. Food and Drug Administration (FDA) approval for SPRAVATO (esketamine) as…
Sage Therapeutics, Biogen get ZURZUVAE FDA approval for postpartum depression treatment
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA)…